Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Pretrain Value, Not Reward: Decoupled Value Policy Optimization
arXiv:2502.16944v2 Announce Type: replace-cross Abstract: In this paper, we explore how directly pretraining a value model simplifies and stabilizes reinforcement learning from human feedback (RLHF). In reinforcement learning, value estimation is the key to policy optimization, distinct from reward supervision. The value function predicts the \emph{return-to-go} of a partial answer, that is, how promising the partial answer is if it were continued to completion. In RLHF, however, the standard p
-
cs.AI, q-bio.NC updates on arXiv.org
-
OpenNovelty: An LLM-powered Agentic System for Verifiable Scholarly Novelty Assessment
arXiv:2601.01576v2 Announce Type: replace-cross Abstract: Evaluating novelty is critical yet challenging in peer review, as reviewers must assess submissions against a vast, rapidly evolving literature. This report presents OpenNovelty, an LLM-powered agentic system for transparent, evidence-based novelty analysis. The system operates through four phases: (1) extracting the core task and contribution claims to generate retrieval queries; (2) retrieving relevant prior work based on extracted que
OpenNovelty: An LLM-powered Agentic System for Verifiable Scholarly Novelty Assessment
-
cs.AI, q-bio.NC updates on arXiv.org
-
OpenNovelty: An LLM-powered Agentic System for Verifiable Scholarly Novelty Assessment
arXiv:2601.01576v1 Announce Type: cross Abstract: Evaluating novelty is critical yet challenging in peer review, as reviewers must assess submissions against a vast, rapidly evolving literature. This report presents OpenNovelty, an LLM-powered agentic system for transparent, evidence-based novelty analysis. The system operates through four phases: (1) extracting the core task and contribution claims to generate retrieval queries; (2) retrieving relevant prior work based on extracted queries via
OpenNovelty: An LLM-powered Agentic System for Verifiable Scholarly Novelty Assessment
-
cs.AI, q-bio.NC updates on arXiv.org
-
WisPaper: Your AI Scholar Search Engine
arXiv:2512.06879v1 Announce Type: cross Abstract: Researchers struggle to efficiently locate and manage relevant literature within the exponentially growing body of scientific publications. We present \textsc{WisPaper}, an intelligent academic retrieval and literature management platform that addresses this challenge through three integrated capabilities: (1) \textit{Scholar Search}, featuring both quick keyword-based and deep agentic search modes for efficient paper discovery; (2) \textit{Libr
WisPaper: Your AI Scholar Search Engine
-
cs.AI, q-bio.NC updates on arXiv.org
-
A Brief History of Digital Twin Technology
arXiv:2511.20695v1 Announce Type: new Abstract: Emerging from NASA's spacecraft simulations in the 1960s, digital twin technology has advanced through industrial adoption to spark a healthcare transformation. A digital twin is a dynamic, data-driven virtual counterpart of a physical system, continuously updated through real-time data streams and capable of bidirectional interaction. In medicine, digital twin integrates imaging, biosensors, and computational models to generate patient-specific s
A Brief History of Digital Twin Technology
-
cs.AI, q-bio.NC updates on arXiv.org
-
LLM4AD: Large Language Models for Autonomous Driving - Concept, Review, Benchmark, Experiments, and Future Trends
arXiv:2410.15281v4 Announce Type: replace-cross Abstract: With the broader adoption and highly successful development of Large Language Models (LLMs), there has been growing interest and demand for applying LLMs to autonomous driving technology. Driven by their natural language understanding and reasoning capabilities, LLMs have the potential to enhance various aspects of autonomous driving systems, from perception and scene understanding to interactive decision-making. In this paper, we first
LLM4AD: Large Language Models for Autonomous Driving - Concept, Review, Benchmark, Experiments, and Future Trends
-
Omics In Lung
-
Role of the "inflammation-immunity-metabolism" network in non-small cell lung cancer: a multi-omics analysis
Discov Oncol. 2025 May 21;16(1):847. doi: 10.1007/s12672-025-02692-z.ABSTRACTLung cancer remains one of the leading causes of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for 85% of cases worldwide. NSCLC pathogenesis and progression are intricately linked to inflammatory stimuli, immune evasion, and metabolic reprogramming. In this study, the impact of inflammation, immunity, and metabolism on NSCLC was investigated by a Mendelian randomization analysis taking 91
Role of the "inflammation-immunity-metabolism" network in non-small cell lung cancer: a multi-omics analysis
Discov Oncol. 2025 May 21;16(1):847. doi: 10.1007/s12672-025-02692-z.
ABSTRACT
Lung cancer remains one of the leading causes of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for 85% of cases worldwide. NSCLC pathogenesis and progression are intricately linked to inflammatory stimuli, immune evasion, and metabolic reprogramming. In this study, the impact of inflammation, immunity, and metabolism on NSCLC was investigated by a Mendelian randomization analysis taking 91 inflammatory factors, 731 immune cells, and 1400 metabolites as exposures, and the FinnGen database NSCLC cohort (ncases = 5315, ncontrol = 314,193) was the outcome. A number of metabolites, inflammatory proteins, and immune cells were identified as potentially associated with NSCLC based on mendelian randomization analysis. Validation in the UK Biobank database lung cancer cohort (ncases = 2671, ncontrols = 372,016) further confirmed the inhibitory role of the metabolite N-acetyl-aspartyl-glutamate (NAAG) on lung cancer. Subsequently, single-cell and protein-protein interaction analyses identified inflammatory protein expression patterns in NSCLC, distribution ratios of immune cells in NSCLC. Subsequent multi-omics network analysis showed key interaction nodes between NAAG and inflammatory proteins. These findings enhance the understanding of the roles of inflammation, immunity, and metabolism in NSCLC occurrence and progression, offering potential targets and strategies for further research on its treatment and management.
PMID:40397292 | PMC:PMC12095725 | DOI:10.1007/s12672-025-02692-z
-
(Multiomics OR Omics) AND (Pancreatic)
-
A deep learning framework for <em>in silico</em> screening of anticancer drugs at the single-cell level
Natl Sci Rev. 2024 Dec 10;12(2):nwae451. doi: 10.1093/nsr/nwae451. eCollection 2025 Feb.ABSTRACTTumor heterogeneity plays a pivotal role in tumor progression and resistance to clinical treatment. Single-cell RNA sequencing (scRNA-seq) enables us to explore heterogeneity within a cell population and identify rare cell types, thereby improving our design of targeted therapeutic strategies. Here, we use a pan-cancer and pan-tissue single-cell transcriptional landscape to reveal heterogeneous expres
A deep learning framework for <em>in silico</em> screening of anticancer drugs at the single-cell level
Natl Sci Rev. 2024 Dec 10;12(2):nwae451. doi: 10.1093/nsr/nwae451. eCollection 2025 Feb.
ABSTRACT
Tumor heterogeneity plays a pivotal role in tumor progression and resistance to clinical treatment. Single-cell RNA sequencing (scRNA-seq) enables us to explore heterogeneity within a cell population and identify rare cell types, thereby improving our design of targeted therapeutic strategies. Here, we use a pan-cancer and pan-tissue single-cell transcriptional landscape to reveal heterogeneous expression patterns within malignant cells, precancerous cells, as well as cancer-associated stromal and endothelial cells. We introduce a deep learning framework named Shennong for in silico screening of anticancer drugs for targeting each of the landscape cell clusters. Utilizing Shennong, we could predict individual cell responses to pharmacologic compounds, evaluate drug candidates' tissue damaging effects, and investigate their corresponding action mechanisms. Prioritized compounds in Shennong's prediction results include FDA-approved drugs currently undergoing clinical trials for new indications, as well as drug candidates reporting anti-tumor activity. Furthermore, the tissue damaging effect prediction aligns with documented injuries and terminated discovery events. This robust and explainable framework has the potential to accelerate the drug discovery process and enhance the accuracy and efficiency of drug screening.
PMID:39872221 | PMC:PMC11771446 | DOI:10.1093/nsr/nwae451